Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCHW) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for Envoy Medical (COCHW) over the last 4 years, with Q3 2025 value amounting to $3.6 million.

  • Envoy Medical's Cash & Equivalents fell 1962.03% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 1962.03%. This contributed to the annual value of $5.5 million for FY2024, which is 2999.05% up from last year.
  • According to the latest figures from Q3 2025, Envoy Medical's Cash & Equivalents is $3.6 million, which was down 1962.03% from $5.3 million recorded in Q2 2025.
  • Over the past 5 years, Envoy Medical's Cash & Equivalents peaked at $16.8 million during Q3 2023, and registered a low of $68000.0 during Q2 2023.
  • Over the past 4 years, Envoy Medical's median Cash & Equivalents value was $3.6 million (recorded in 2025), while the average stood at $3.6 million.
  • The largest annual percentage gain for Envoy Medical's Cash & Equivalents in the last 5 years was 547621.43% (2023), contrasted with its biggest fall of 8574.27% (2023).
  • Over the past 4 years, Envoy Medical's Cash & Equivalents (Quarter) stood at $183000.0 in 2022, then skyrocketed by 2204.92% to $4.2 million in 2023, then grew by 29.99% to $5.5 million in 2024, then plummeted by 35.14% to $3.6 million in 2025.
  • Its Cash & Equivalents stands at $3.6 million for Q3 2025, versus $5.3 million for Q2 2025 and $5.3 million for Q1 2025.